Business
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
BOSTON, August 21, 2025--PureTech Demonstrates Strategic and Scientific Leadership in Idiopathic Pulmonary Fibrosis at 2025 IPF Summit
About this update from Puretech Health Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":7367,"height":2362,"url":"https://media.zenfs.com/en/business-wire.com/6487fbaa96d0f25765e833a23c2cb7e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BUF73HcThpIWO.xO.spVRw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6487fbaa96d0f25765e833a23c2cb7e7","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/BIbfY.Y3aQylAQ64O9pl0A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/6487fbaa96d0f25765e833a23c2cb7e7","width":1200,"height":385}},"lazy":false},{"type":"text","content":"Deupirfenidone to be advanced by PureTech’s newly launched Founded Entity, Celea Therapeutics","length":93,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, August 21, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, demonstrated its growing leadership in idiopathic pulmonary fibrosis (IPF) at the 2025 IPF Summit this week in Boston. The Company highlighted the strength of its Phase 2b ELEVATE IPF trial data supporting the advancement of deupirfenidone (LYT-100) into Phase 3 by its newest Founded Entity, Celea Therapeutics ("Celea"), and shared new patient preference data and insights shaped by deep engagement across the IPF treatment ecosystem.","length":697,"tagName":"p"},{"type":"text","content":""With deupirfenidone demonstrating compelling efficacy, we are taking a holistic approach to Phase 3 planning — one that is informed by a deep understanding of the needs of patients, clinicians, and payers alike," said Camilla Graham, MD, MPH, Senior Vice President of Medical Affairs at PureTech. "After more than a decade without meaningful therapeutic advancement, the IPF treatment landscape is beginning to shift. To deliver real impact, innovation must extend beyond the molecule — into clinical trial design, patient and provider education, and access. That’s the bar we’ve set with deupirfenidone."","length":626,"tagName":"p"},{"type":"text","content":"Balancing Efficacy and Safety...